US FDA greenlights first ever treatment for rare metabolic disorder

Soleno Therapeutics

26/03/2025 21:05

March 26 (Reuters) - The U.S. Food and Drug Administration approved Soleno Therapeutics' SLNO.O drug to treat a rare genetic disorder on Wednesday, making it the first treatment available for patients who experience feelings of intense and persistent hunger.

 (Reporting by Sneha S K and Bageshri Banerjee in Bengaluru; Editing by Krishna Chandra Eluri and Alan Barona)

 ((Sneha.SK@thomsonreuters.com))